Austin, Texas-based OsteoCentric Technologies, Inc., a developer of bone fixation technology for orthopedics and dental, has acquired the Integrity-SI™ Fusion System from Lincotek Medical, a medical global contract manufacturer with headquarters in Trento, Italy.
OsteoCentric Technologies Acquires New Tech
2 min read Premium comments
Secondary#integritysifusion#osteocentric#lincotekmedical
OsteoCentric enables surgeons to secure implants to bone via mechanical integration. Its flagship technology is its Unifi Mechanical Integration (UnifiMI™) technology. The company developed the technology to address implant instability. According to OsteoCentric, “UnifiMI mechanically integrates with bone to provide instant and lasting multi-axial stability and load sharing in normal, compromised and osteoporotic bone.”
OsteoCentric will integrate the Integrity-SI Fusion System with UnifiMI. According to the press release, it will apply mechanical integration “to optimize the stability of the Integrity-SI implant.”
OTW spoke with OsteoCentric Technologies Chief Marketing Officer Gavin Sontag about the acquisition and the company’s initial interest in the Integrity-SI Fusion System. Sontag told OTW, “Our initial interest in the System stemmed from two things:
- The System’s focus on the core principles of fusion (decortication and grafting at the fusion site & compressive stable fixation across the fusion site) in both the procedural steps and the implants.
- Our unique opportunity to apply our new method of securing implants to bone, UnifiMI (Mechanical Integration), to a proven, FDA-cleared system in pelvic/SI [sacroiliac] surgery.”
Sontag continued to describe to OTW what sets the Integrity-SI Fusion System apart from its competitors, stating, “The MIS Percutaneous System strictly adheres to core principles of bone/joint fusion including joint decortication, fusion site bone grafting, and acute and long term compression with stability. These already established System principles, coupled with the innate advantages of our proprietary technology, UnifiMI, will help facilitate optimal compression, acute stability and ideal bone graft integration and bone fusion.”
Sontag also discussed the company’s goals for the upcoming year, commenting, “We are already hard at work at applying UnifiMI to the Integrity-SI System and we are confident in being able to offer that ‘next generation’ in early 2022. In parallel, we are targeting to introduce, train and support the use of our system with another 35-50 surgeon customers in both the spine and trauma specialties.”
Sontag added with a smile, “That should be keeping us very busy over the next 15 months.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.